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Abstract 28 
C-type lectin SIGNR1 directly recognizes Candida albicans and zymosan, and has 29 
been considered to share properties of polysaccharide recognition with human (h)DC-SIGN. 30 
However, the precise specificity of SIGNR1 and difference from that of hDC-SIGN remains to 31 
be elucidated. We prepared soluble forms of SIGNR1 and hDC-SIGN and conducted 32 
experiments to examine their respective specificities. 33 
Soluble SIGNR1 (sSIGNR1) bound several types of live clinical isolate C. albicans 34 
strains in an EDTA-sensitive manner. Inhibition analyses of sSIGNR1 binding by glycans from 35 
various yeast strains demonstrated that SIGNR1 preferentially recognizes N-glycan α-mannose 36 
side chains in Candida mannoproteins, as reported in hDC-SIGN. Unlike shDC-SIGN, however, 37 
sSIGNR1 recognized not only S. cerevisiae but also C. albicans J-1012 glycan even after 38 
α-mannosidase treatment that leaves only β1,2-mannose capped α-mannose side chains. In 39 
addition, the glyco-microarray analyses showed that sSIGNR1 binds mannans from C. albicans 40 
and S. cerevisiae, but does not recognize Lewisa/b/x/y antigen polysaccharides as in shDC-SIGN. 41 
Consistent with these results, RAW264.7 cells expressing hDC-SIGN of which the carbohydrate 42 
recognition domain (CRD) was replaced with that of SIGNR1 (RAW-chimera) produced 43 
comparable amounts of IL-10 in response to glycans from C. albicans and S. cerevisiae, but 44 
those expressing hDC-SIGN produced less IL-10 to S. cerevisiae than C. albicans. Furthermore, 45 
RAW-hDC-SIGN cells remarkably reduced IL-10 production after α-mannosidase treatment 46 
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compared with RAW-chimera. 47 
These results indicate that SIGNR1 recognizes C. albicans/yeast through a partly 48 
distinct specificity from its homologue hDC-SIGN. 49 
50 
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Introduction 50 
Numerous microbes are covered with the polysaccharides. Recognition of the 51 
polysaccharides by pattern recognition receptors (PRRs), including lectins, is vital in order to 52 
recognize pathogens, since recognition of the outermost components is the first interactive step 53 
with immune cells during infection to evoke innate and adaptive immune responses. 54 
Candida albicans is an opportunistic agent of infection in immune compromised 55 
patients. In the host innate immune system, several types of receptors for sensing ligands on the 56 
microbe have been defined, e.g., C-type lectins and toll-like receptors (TLRs) (18). Ligands for 57 
these receptors are present in the outer structure of microbes. However, some ligands are 58 
sequestered by the outermost polysaccharides, which consist of mannoproteins, as reported in the 59 
case of β-glucan, a ligand for Dectin-1 (6). Mannoproteins are rich in polysaccharides composed 60 
of mostly α- and β-mannose and recognized by mannose/mannan type lectins.  61 
C-type lectin human (h)DC-SIGN (CD209) has been shown to interact with a wide 62 
range of pathogens, including microbes, viruses and protozoa (11) via mannose and fucose 63 
moieties on the surface of the pathogens. Microbes such as Mycobacterium tuberculosis and C. 64 
albicans are endocytosed and processed for antigen presentation to induce the subsequent T 65 
cell-mediated immune responses. However, the recognition also induces immunosuppressive 66 
responses in cooperation with TLRs (8). 67 
Mice have eight hDC-SIGN homologues (19, 20). One of these homologues, SIGNR1, 68 
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is structurally related to hDC-SIGN based on its long neck domain. SIGNR1 is expressed on 69 
particular subsets of macrophages (Mφ)/dendritic cells (DC) in the marginal zones of the spleen, 70 
resident peritoneal cavity, medulla of lymph nodes, skin and lamina propria (4, 10, 17, 30). 71 
SIGNR1 on these cells plays a role as a sentinel in the recognition of pathogens through capsular 72 
polysaccharides. In fact, SIGNR1 on marginal zone Mφ recognizes Streptococcus pneumoniae 73 
(10), leading to efficient activation of the complement system in situ (9). 74 
Previously, we reported that SIGNR1 recognizes Gram-negative bacteria (Salmonella 75 
typhimurium and Escherichia coli) and C. albicans (27). The former are recognized through their 76 
non-reductive end of the lipopolysaccharide core sequence by SIGNR1 (17). This is also the case 77 
of hDC-SIGN in recognition of E. coli (13). Recently, hDC-SIGN has been reported to strongly 78 
recognize the α-mannose structure of N-glycan side chains of C. albicans, but weakly that of S. 79 
cerevisiae (2). However, the recognition motif on C. albicans by SIGNR1 is not clear at present.  80 
Therefore, we aimed to elucidate the properties of SIGNR1 in the recognition of 81 
polysaccharide on C. albicans. To this end, we prepared soluble forms of SIGNR1 (sSIGNR1) 82 
and hDC-SIGN (shDC-SIGN) and used structurally distinguished glycans purified from various 83 
types of C. albicans and S. cerevisiae as well as respective microbes. The results indicate that 84 
sSIGNR1 binds equally well to glycans from S. cerevisiae as to C. albicans. Furthermore, 85 
sSIGNR1, but not shDC-SIGN, was shown to readily recognize C. albicans glycan treated with 86 
α-mannosidase. In addition, a glyco-microarray based on an evanescent-field fluorescence 87 
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detection method clearly revealed that sSIGNR1 binds α-mannose monosaccharide and mannans 88 
from C. albicans and S. cerevisiae, but dose not recognize Lewisa/b/x/y antigen polysaccharides as 89 
in shDC-SIGN. Different properties in recognition of yeast glycans between SIGNR1 and 90 
hDC-SIGN CRD were also observed in induction of IL-10 from RAW264.7 cells. 91 
92 
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Materials and methods 92 
Cells and cultures. Maintenance of human embryonic kidney (HEK) 293T cells and 93 
macrophage-like RAW264.7 cells and preparation of RAW264.7 expressing SIGNR1 94 
(RAW-SIGNR1) were as described previously (27). In order to prepare RAW-hDC-SIGN, 95 
cDNA encoded hDC-SIGN (kindly provided by Dr. R.M. Steinman, Rockefeller University) was 96 
cloned into pMX-IRES-puromycin (12). RAW264.7 cells were transfected by the plasmid with 97 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer’s protocol. 98 
RAW264.7 cells expressing hDC-SIGN (RAW-hDC-SIGN) were maintained in the presence of 99 
4 µg/ml puromycin (InvivoGen, San Diego, CA). To prepare RAW264.7 cells expressing 100 
chimeric lectin consisting of hDC-SIGN and SIGNR1 (RAW-chimera), cDNA fragments 101 
encoding amino acids 1 - 253 (corresponding to cytosolic-neck domain of hDC-SIGN) and 193 - 102 
325 (corresponding to CRD of SIGNR1) were amplified using KOD polymerase (Toyobo, 103 
Tokyo, Japan) using primer pairs (5’-ggtggtacgggaattcatgagtgactccaaggaaccaagac-3’, 104 
5’-ggcacaggcgttccac-3’) and (5’-tggaacgcctgtgccgactctgcccctgggactggacattc-3’, 105 
5’-atttacgtagcggccgcctagccttcagtgcatggggttgc-3’), respectively. These were introduced into Eco 106 
RI - Not I site of pMX-IRES-puromycin using the In-Fusion PCR Cloning System (Clontech, 107 
Mountain View, CA). RAW264.7 cells were transfected by the plasmid as described above. 108 
 109 
Reagents and yeast strains. Alexa647-coupled hamster anti-SIGNR1 mAb 22D1 and rabbit 110 
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anti-hDC-SIGN Ab (H-200) were purchased from eBioscience (San Diego, CA) and Santa Cruz 111 
Biotechnology (Santa Cruz, CA), respectively. Anti-hDC-SIGN mAb (DCS-8C1; eBioscience) 112 
was labeled with Alexa-555 (Invitrogen) in accordance with the manufacturer’s protocol. 113 
Glycogen of bovine liver type IX (G0885) and Jack bean (Canavalia ensiformis) α-mannosidase 114 
(EC 3.2.1.24) were from Sigma-Aldrich (Irvine, CA). C. albicans (J-1012: serotype A, 115 
NBRC1060 and NIH B-792: serotype B, NBRC10108), C. lusitaniae (NBRC1019) and S. 116 
cerevisiae X2180-1A (WT) (BY21559) were obtained from the Biological Resource Center of  117 
the National Institute of Technology and Evaluation (Tokyo, Japan). C. albicans (JCM1542) was 118 
from the Japan Collection of Microorganisms, RIKEN (Saitama, Japan). 119 
 120 
Preparation of mannan from yeast strains. Glycan was prepared from mannoprotein of the 121 
blastospore (yeast) form using Fehling’s solution, as previously described (24). Glycans used in 122 
this study were purified from strains of C. albicans J-1012 (25), C. albicans NIH B-792 (22), C. 123 
stellatoidea (24), C. parapsilosis (22), C. lusitaniae (23), S. cerevisiae (WT) (1), S. cerevisiae 124 
(mnn1/mnn4) (1) and S. cerevisiae (mnn2) (21). The α-mannosidase treatment of C. albicans 125 
J-1012 mannan was carried out in 50 mM sodium acetate buffer (pH 4.6) containing 20 units of 126 
α-mannosidase at 37°C for 48 h. 127 
 128 
Preparation of sSIGNR1 and shDC-SIGN and binding analyses to microbes. Soluble lectin 129 
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(sLectin) tetramers, such as sSIGNR1 and shDC-SIGN, were prepared as described (26). Briefly, 130 
cDNA fragments encoding their extracellular domains were cloned into pEXPR-IBA44 (IBA, 131 
Göttingen, Germany) to add N-terminal BM40 secretion signal and Strep-Tag II sequences, 132 
followed by the transfer into pEF6/V5-His (Invitrogen). HEK293T cells were then transfected 133 
with each plasmid using the calcium phosphate method (3) and cultured in serum-free medium 134 
293 SFM II (Invitrogen) for the last 48 hr. sSIGNR1 and shDC-SIGN in the supernatant were 135 
purified using Strep-Tactin Sepharose (IBA) in accordance with the manufacturer’s protocol (> 136 
95% of purity by SDS-PAGE). 137 
Purified sLectins (2.5 µg/ml) were incubated with PE-labeled Strep-Tactin (7.5 µg/ml) 138 
in 18 µl of Hanks' balanced salt solution (pH 8.3) (binding buffer) for 2 h at 4°C and for a further 139 
10 min at 37°C. The tetramers thus formed were incubated with 5 x 106 live microbes for 4 h at 140 
4°C in the presence of 1% BSA (total volume 25 µl). After washing with the binding buffer, the 141 
amount of bound PE-Strep-Tactin was measured by Gemini EM (Molecular Devices, Sunnyvale, 142 
CA). The direct binding of sSIGNR1 is shown as an arbitrary unit of fluorescence intensity. 143 
The % inhibition was calculated using the following formula: [1 - (fluorescence intensity of C. 144 
albicans by the staining with sLectin plus inhibitor - that without sLectin) / (that with sLectin 145 
without inhibitor - that without sLectin)] x 100. 146 
 147 
Lectin ELISA. sSIGNR1 and shDC-SIGN were formed by incubating sLectins (62.5 ng) with 148 
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HRP-Strep-Tactin (12.5 ng) in 20 µl of the solution as above. Microtiter plates were coated with 149 
50 µl of mannan/glycan (5 mg/ml) in 50 mM sodium bicarbonate buffer (pH 9.6) for 12 h at 4°C, 150 
followed by the incubation with 2.5% BSA at room temperature for 2 h after washing with 25 151 
mM Tris-HCl pH8.3 + 150 mM NaCl. The plates were then incubated with sSIGNR1 or 152 
shDC-SIGN in the presence of 1% BSA for 2 h at 4°C. For inhibition experiments, sLectin 153 
tetramer was pre-incubated with inhibitors for 1 h at 4°C before adding to plates. After washing, 154 
binding of sLectin tetramer was measured as the absorbance of TMB (eBioscience) at 450 nm by 155 
VERSAmax (Molecular Devices). The % inhibition was calculated as above. 156 
 157 
Inhibition of FITC-dextran binding to RAW-SIGNR1 with glycans. RAW-SIGNR1 cells (2 158 
x 105 cells) were pre-incubated with various types of glycan and EDTA (25 mM) for 30 min at 159 
4ºC and then mixed with 80 µg/ml of FITC-dextran (2,000 kDa; Sigma-Aldrich) for 4 h at 4ºC. 160 
Binding of FITC-dextran was analyzed by a flow cytometer. The % inhibition was calculated 161 
using the following formula: [1 - (mean fluorescence intensity (MFI) of RWA-SIGNR1 cells 162 
with FITC-dextran plus inhibitor- that without FITC-dextran) / (that with FITC-dextran without 163 
inhibitor - that without FITC-dextran)] x 100. 164 
 165 
Glyco-microarray analyses of sLectins by evanescent-field fluorescence detection. The 166 
glyco-microarray analysis was performed as described (28). To form immune complex, 167 
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sSIGNR1 and shDC-SIGN (10 µg/ml) were pre-incubated with Alexa647-anti-SIGNR1 (22D1) 168 
and Alexa555–anti-hDC-SIGN (DCS-8C1; 1 µg/ml) for 15 min at room temperature in 25 mM 169 
Tris-HCl buffer (pH 7.4) containing 0.8% NaCl, 1% (v/v) Triton-X100, and 2 mM CaCl2 with or 170 
without 10 mM EDTA. This complex was directly added to the array immobilized with 171 
multivalent glycan ligands (Supplementary Fig. S1), followed by incubation overnight at 20°C. 172 
Binding was then detected using an evanescent-field fluorescence-assisted scanner. Data were 173 
analyzed with the Array Pro analyzer ver. 4.5 (Media Cybernetics, Bethesda, MD). 174 
 175 
IL-10 production of RAW264.7 transfectants by stimulation in microplates coated with 176 
glycan. Non-treated plates were pre-coated with 600 µg/ml glycan in PBS for 12 h. After 177 
blocking with RPMI1640 containing 10% FCS for 30 min, RAW264.7 transfectants (5 x 104 178 
cells) were cultured in the presence of 100 ng/ml ultra pure LPS (Invitrogen) for 24 h. IL-10 in 179 
the supernatants was analyzed using the Cytometric Bead Array (CBA) for mouse inflammation 180 
kit (BD Biosciences, Franklin Lakes, NJ). 181 
 182 
Statistical analysis. Data are expressed as the means ± SD of triplicate assays. Statistical 183 
significance was determined by the two-tailed Student’s t-test or multiple comparisons with 184 
Tukey's multiple range test. All experiments were performed two or more times and 185 
representative results are shown. 186 
187 
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Results and Discussion 187 
SIGNR1 recognizes various types of Candida strains. Each Candida strain has a unique set of 188 
oligomannose side chains, generating a great diversity of N-glycans (see Fig. 1A) compared with 189 
that of O-glycans. Moreover, N-glycans account for more than 95% of glycans in the surface 190 
mannoproteins. 191 
Therefore, we first examined the direct binding of sSIGNR1 to several Candida strains 192 
(Fig. 1B). We used sSIGNR1 tetramerized with Strep-Tactin, because the affinity of sSIGNR1 193 
monomer is weak (20). This method not only helps to increase the affinity of sSIGNR1 but also 194 
helps to avoid the formation of large complexes using Fc-fusion lectins polymerized with anti-Fc 195 
polyclonal Ab. Before using this sSIGNR1-tetramer for experiments, we confirmed that 196 
sSIGNR1-tetramer bound to mannan-agarose was eluted with EDTA (data not shown), although 197 
the yield was less than half the amounts applied. sSIGNR1 bound clinical isolate live C. albicans 198 
JCM1542 (serotype A) in an EDTA-sensitive manner, indicating that sSIGNR1 binding occurs 199 
via the carbohydrate recognition domain (CRD). The other clinical isolate strains, C. albicans 200 
J-1012 (serotype A) and NIH B-792 (serotype B), were also recognized by sSIGNR1, although 201 
sSIGNR1 binding was much less to nosocomial strain C. lusitaniae. 202 
It is of note that sSIGNR1 binds to S. cerevisiae comparably to clinical isolate C. 203 
albicans  (Fig. 1B), and its binding to C. albicans J-1012 microbes was equally inhibited by 204 
N-glycans from S. cerevisiae (WT and mnn1/mnn4) and C. albicans NIH B-792 as C. albicans 205 
Takahara et al. 
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J-1012 (Fig. 1C). 206 
 207 
SIGNR1 possibly recognizes α-mannose in side chains of C. albicans N-glycan. To delineate 208 
the polysaccharide structure recognized by SIGNR1, inhibition experiments with lectin ELISA 209 
were conducted using N-glycans from the various yeast strains listed (Fig. 1A and Table I). 210 
The direct binding of sSIGNR1 to C. albicans J-1012 N-glycan, which is composed of 211 
complexed side chains, was inhibited by glycans from several types of microbes: C. albicans 212 
NIH B-792 and C. stellatoidea glycans lacking β1,2-mannose, C. parapsilosis glycan 213 
lacking β1,2-mannose and α1,6-branched mannose, and S. cerevisiae WT glycan composed of 214 
short side chains lacking β1,2-mannose and α1,6-branched mannose (Fig. 2A). These glycans 215 
share the α1,2-mannose side chain structure, suggesting that SIGNR1 recognizes similar moiety 216 
in N-glycan as hDC-SIGN (2). Moreover, S. cerevisiae 4484-24D-1 (mnn1/mnn4) glycan, which 217 
lacks phosphorylated mannose (PM), β1,2-mannose, α1,3-mannose, and α1,6-branched mannose 218 
but possesses the short (mono- or di-) mannose side chain structure, appeared to be recognized 219 
by SIGNR1. However, S. cerevisiae X2180-1A-5 (mnn2) glycan, which lacks all side chains, 220 
wasn’t effective (Figs. 2A and B), suggesting the crucial involvement of the side chain structure. 221 
In addition, C. lusitaniae glycan, the side chain of which is composed of more than 75% of 222 
β1,2-mannose (mono- ~ tri-β-mannose)-capped side chain (23), was also ineffective in inhibiting 223 
the sSIGNR1 binding (Figs. 2A and B), implying that these β1,2- mannoses disturb the access of 224 
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SIGNR1 to the α-di-mannose to some extent. Glycogen itself had no effect. As in the case of 225 
sSIGNR1 binding to microbes, that to C. albicans J-1012–derived N-glycan was EDTA-sensitive 226 
(Fig. 2A). 227 
Interestingly, treatment of C. albicans J-1012 mannan with α-mannosidase, which 228 
removed the α-mannose side chains other than the β1,2-mannose-capped side chains (see Fig. 229 
1B) (14), did not affect the inhibitory activity (Fig. 2A). This result also indicates that 230 
β1,2-mannose capped α-mannose side chains in the N-glycan are sufficient to be recognized by 231 
SIGNR1. We also obtained similar results when mannan from S. cerevisiae (M7504; 232 
Sigma-Aldrich) was employed to coat plastic plates in lectin ELISA (data not shown). Therefore, 233 
it is feasible that SIGNR1 recognizes long internal α-mannose (tri- or more-mannose) capped 234 
with β1,2-mannose in addition to α-mannose side chains. 235 
Since RAW-SIGNR1 cells effectively bind and endocytose high molecular weight 236 
FITC-dextran in an EDTA-sensitive manner (27), we carried out the inhibition analysis using 237 
RAW-SIGNR1 cells to bind FITC-dextran instead of lectin ELISA (Fig. 2C).  The inhibition 238 
activities of glycans from C. albicans J-1012 and NIH B-792, and S. cerevisiae and its mutant 239 
(mnn1/mnn4) were again comparably effective. The treatment of C. albicans J-1012 glycan with 240 
α-mannosidase was also ineffective in reducing the inhibitory activity. In addition, low 241 
efficiencies of glycans from S. cerevisiae (mnn2) and C. lusitaniae were also confirmed in this 242 
experimental system. When resident peritoneal Mφ that express SIGNR1 (27) were used, similar 243 
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results were obtained (data not shown). Together with the results using N-glycan only consisting 244 
of α-mannose in side chain, these results strengthen the possibility that SIGNR1 recognizes both 245 
α-mannose side chain and β1,2-mannose capped α-mannose side chains composed of more than 246 
tri-mannoses in N-glycan. 247 
 248 
Specificity of N-glycan recognition by hDC-SIGN. Cambi et al. previously reported that 249 
hDC-SIGN recognizes glycans of S. cerevisiae strains less efficiently than those of Candida 250 
strains (2). In contrast, SIGNR1 equally recognized glycans from both wild type and mnn1/mnn4 251 
mutant of S. cerevisiae as C. albicans, suggesting that the specificities of hDC-SIGN and 252 
SIGNR1 are somehow different from each other. In order to examine this possibility, we 253 
prepared shDC-SIGN and compared the sugar specificity with that of sSIGNR1. 254 
In lectin ELISA, the binding of shDC-SIGN to C. albicans J-1012 glycan was more 255 
sensitive to fucose than mannose, and less sensitive to glucose and GlcNAc (Fig. 3A), as 256 
reported (16). Results using this probe showed that shDC-SGIN bound comparably well to C. 257 
albicans J-1012 and NIH B-792 (Fig. 3B). Unlike sSIGNR1, shDC-SIGN bound less to S. 258 
cerevisiae microbes, as reported (2). 259 
In addition, shDC-SIGN binding to C. albicans J-1012 glycan was not efficiently 260 
blocked by glycans from S. cerevisiae and mnn1/mnn4 mutants (Fig. 3C), indicating different 261 
specificity in N-glycan recognition between hDC-SIGN and SIGNR1. It is worth noting that 262 
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treating C. albicans J-1012 glycan with α-mannosidase dramatically reduced its inhibitory 263 
activity (Fig. 3C). We further confirmed the abrogation of inhibitory activity of N-glycan from C. 264 
albicans J-1012 by α-mannosidase treatment by titrating its dose (Fig. 3D), showing that the 265 
reduced activity is nearly comparable to that of S. cerevisiae. These results suggested that 266 
hDC-SIGN only recognizes the α1,2-mannose at the non-reductive end of α-mannose side 267 
chains, but not the internal α1,2-mannose capped with β1,2-mannose and short α-mannose 268 
chains that are recognized by SIGNR1, of the N-glycan side chains in mannoprotein. 269 
It has been reported that another SIGNR lectin, SIGNR3, also recognizes C. albicans 270 
(27) and that its saccharide specificity resembles that of hDC-SIGN (20). Based on the inhibition 271 
assay using lectin ELISA, SINGR3 was shown to bind a little more efficiently to wild type and 272 
the mnn1/mnn4 mutant of S. cerevisiae than hDC-SIGN but less so than SIGNR1 273 
(Supplementary Fig. S2). 274 
 275 
Glyco-microarray analyses of SIGNR1 and hDC-SIGN. Previously, Powlesland et al. 276 
reported that sSIGNR1 did not bind any ligand on array using the regular method (20), 277 
suggesting a weak affinity of SIGNR1. However, a sensitive glyco-microarray, based on an 278 
evanescent-field fluorescence-assisted detection, has recently been developed (28). This method, 279 
in which analysis was performed in the presence of lectin probe without washing, enabled us to 280 
detect weak glycan-lectin interactions in the equilibrium state (15, 29), possibly representing 281 
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genuine interactions of ligand and cellular lectin. 282 
An array plate immobilized with the glycans indicated (Fig. 4A and Supplementary Fig. 283 
S1) was visualized by staining with Alexa647-coupled sSIGNR1/anti-SIGNR1 mAb complex 284 
(Fig. 4B). The results clearly show that SIGNR1 binds to α-mannose and yeast mannans from C. 285 
albicans and S. cerevisiae, but not β-mannose, in an EDTA-sensitive manner (Figs. 4B and C). 286 
Of note, SIGNR1 did not recognize fucose-containing moieties, such as Fucα2Gal and 287 
Lewisa/b/x/y antigen. The binding of sSIGNR1 to heparin is likely to be false positive, because of 288 
the insensitivity to EDTA. 289 
We previously performed array analyses using shDC-SIGN-Fc fusion as a probe (28). 290 
However, structural forms between SIGNR1 and shDC-SIGN-Fc were different and this made it 291 
difficult to compare the precise sugar specificities. Therefore, we again performed glyco-array 292 
analysis using shDC-SIGN dimer as in sSIGNR1. The results clearly showed the recognition of 293 
fucose-containing glycans and C. albicans, but not S. cerevisiae, mannan by shDC-SIGN (Fig. 294 
4D), being consistent with our results in lectin ELISA and direct binding to microbes. 295 
However, there are some discrepancies in our current observation and previous array 296 
results. It has been shown that SIGNR1 can recognize fucose-containing moiety using 297 
glyco-array and solid phase competition binding assays (5). One of our previous microarray 298 
analyses also demonstrated that hDC-SIGN-Fc fusion was able to bind to glycans from C. 299 
albicans and S. cerevisiae (28). In both reports, lectin CRD was fused with the Fc portion of IgG 300 
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and polymerized with anti-Fc polyclonal Ab, giving rise to a very large and multi-valent 301 
complexed probe. In the current glyco-microarray analyses, we utilized dimerized lectin probes, 302 
which possibly have lower avidity than those used in previous studies, enabling us to uncover the 303 
difference in binding activity of shDC-SIGN to S. cerevisiae and C. albicans glycan.  304 
 305 
Biological significance of the different sugar specificity between SIGNR1 and hDC-SIGN in 306 
IL-10 production using RAW264.7 transfectants. To examine the biological significance of 307 
distinct saccharide recognition between SIGNR1 and hDC-SIGN, we measured IL-10 production 308 
by RAW-SIGNR1 and RAW-hDC-SIGN cells, because hDC-SIGN on DCs is known to induce 309 
IL-10 production by recognizing C. albicans (7), and lamina propria DCs expressing SIGNR1 310 
are also capable of producing IL-10 (30). After stimulation with C. albicans J-1012 microbe and 311 
glycan coated on plastic plate, RAW-hDC-SIGN, but not RAW-SIGNR1, produced IL-10 (data 312 
not shown). Therefore, we prepared RAW264.7 cells expressing the chimeric hDC-SIGN 313 
molecule (RAW-chimera), of which CRD was replaced with SIGNR1 CRD, to compare glycan 314 
recognition specificity in terms of the induction of IL-10 production. The RAW-chimera cells 315 
expressed comparable levels of lectin to that of RAW-hDC-SIGN cells (Fig. 5A). Upon 316 
stimulation with S. cerevisiae X2180-1A (WT) glycan, RAW-hDC-SIGN and RAW-chimera 317 
cells produced equivalent amounts of IL-10 (Fig. 5B, upper panel). RAW-hDC-SIGN produced 318 
much less IL-10 in response to S. cerevisiae than C. albicans glycan in comparison with 319 
Takahara et al. 
 
 
  
 
20 
 
RAW-chimera (Fig. 5B, lower panel). Interestingly, in the case of C. albicans J-1012 glycan, 320 
RAW-hDC-SIGN produced more IL-10 than RAW-chimera (Fig. 5B, upper panel). However, 321 
the former significantly reduced IL-10 production after α-mannosidase treatment compared with 322 
the latter (Fig. 5C), being consistent with the results showing that SIGNR1, but not hDC-SING, 323 
recognizes β-mannose capped α-mannose side chains in C. albicans glycan. 324 
 It is feasible that C. albicans induces higher IL-10 production than S. cerevisiae via 325 
hDC-SIGN on DCs in humans, leading to the immunosuppressive milieu at the site of infection. 326 
This may explain why C. albicans is more virulent than S. cerevisiae. Regarding the sugar 327 
specificity of SIGNR1, there were no significant differences in the binding specificity to 328 
mannose moieties between C. albicans and S. cerevisiae at the molecular level. However, IL-10 329 
production was slightly but significantly higher in response to C. albicans than S. cerevisiae, 330 
implying that cellular responses by the recognition through lectin receptors is affected by some 331 
other unknown factors. In this study, we used glycans prepared from the blastospore (yeast) form 332 
of each yeast strain. However, it should also be kept in mind that the difference in the growth 333 
form between C. albicans and S. cerevisiae might modulate cellular activity against microbes in 334 
situ. hDC-SIGN in the mouse cells prepared in this study properly transduce signals for IL-10 335 
production. Although it is unknown how hDC-SIGN activates the mouse Src family and 336 
subsequent Raf-1 kinase in this situation, hDC-SIGN likely has a certain motif that is lacking in 337 
SIGNR1, to work in both human and mouse cells for IL-10 production. 338 
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 339 
Collectively, SIGNR1 and hDC-SIGN bind polysaccharides in surface mannoprotein 340 
on live C. albicans. However, SIGNR1 recognizes both α-mannose and β1,2-mannose capped 341 
α-mannose side chains composed of more than tri-mannoses, whereas hDC-SIGN recognizes 342 
only α-mannose at the non-reductive end of the side chains, but not internal α-mannose capped 343 
with β1,2-mannose and short α-mannose chains, of N-glycan side chains in mannoprotein. 344 
Differential recognition of yeast strains by SIGNR1 and hDC-SIGN may be relevant to the 345 
differences in cellular responsiveness. 346 
347 
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Figure legends 452 
Fig. 1. sSIGNR1 binds various types of yeast strains. 453 
(A) Structural diagrams of N-glycan used in this study. Structures of N-glycan of C. albicans 454 
J-1012 (25), C. albicans NIH B-792 (22), C. stellatoidea (24), C. parapsilosis (22) and C. 455 
lusitaniae (23) are adopted from our structural analyses using NMR. Structure of S. cerevisiae 456 
wild type, S. cerevisiae 4484-24D-1 (mnn1/mnn4) and S. cerevisiae X2180-1-A-5 (mnn2) are 457 
based on previous reports (1, 21). Side chains that are digested by treatment with α-mannosidase 458 
in C. albicans J-1012 N-glycan are shaded. The side chain sequence is not specified. (B) Binding 459 
of sSIGNR1 to Candida and S. cerevisiae strains. PE-Strep-Tactin alone (-) or PE-sSIGNR1 (+) 460 
were incubated with the indicated live yeast strains with or without EDTA (25 mM). (C) 461 
Inhibition of sSIGNR1 binding to C. albicans J-1012 by glycans purified from the C. albicans 462 
and S. cerevisiae strains indicated. sSIGNR1 was pre-incubated with 50 µg/ml of glycans before 463 
mixing with microbes. Glycogen was used as a negative control. Inhibition is indicated as the 464 
percent decrease of fluorescence intensity in experimental groups compared with the control 465 
without inhibitor. The results are shown as the mean ± SD of triplicate assays. *p < 0.05 on solid 466 
line by Tukey's multiple range test. Grey lines show no significant differences. 467 
 468 
Fig. 2. Recognition of α-mannose side chains in N-glycan by sSIGNR1. 469 
(A) Inhibition analysis by lectin ELISA. Binding of sSIGNR1 to C. albicans J-1012 glycan 470 
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coated on microtiter plates was analyzed in the presence of glycans (25 µg/ml) purified from 471 
various types of yeast strains. Blocking activities of inhibitors are shown as the % inhibition of 472 
sSIGNR1 binding. (B) Titration of inhibitory activity of glycans from the indicated yeast strains 473 
for sSIGNR1 binding by lectin ELISA. Half of maximal inhibition activity was indicated by 474 
dashed line. (C) Inhibition of FITC-binding to RAW-SIGNR1 cells by glycans. Transfectants 475 
were incubated with the graded dose of glycans as in (B) prior to FITC-dextran. The results are 476 
shown as % inhibition. Results are shown as the mean ± SD of triplicate assays. *p < 0.05 on 477 
solid line by Tukey's multiple range test. Grey lines show no significant differences. 478 
 479 
Fig. 3. Binding of shDC-SIGN to microbes and inhibition of shDC-SIGN binding by glycans.  480 
(A) Inhibition analysis of shDC-SIGN binding by monosaccharides (50 mM) and glycan from C. 481 
albicans J-1012 using lectin ELISA. (B) Binding of shDC-SIGN to yeast strains was analyzed as 482 
in Fig. 1B. (C) Inhibition analysis using glycans from various yeast strains as in Fig. 2A. (D) 483 
Inhibition assay was performed in the presence of graded doses of glycans from the indicated 484 
yeast strains. Half of maximal inhibition activity was indicated by dashed line. The results are 485 
shown as the mean ± SD of triplicate assays. *p < 0.05 on solid line by Tukey's multiple range 486 
test. Grey lines show no significant differences. 487 
 488 
Fig. 4. Glyco-microarray analysis of sSIGNR1. 489 
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(A) The layout of glyco-microarray. (B) Results of the glyco-microarray analyses. Binding of 490 
soluble SIGNR1/Alexa647-anti-SIGNR1 mAb immune complex to the array was performed in 491 
the absence (left panel) or presence (right panel) of 10 mM EDTA and detected by an 492 
evanescent-field fluorescence-assisted scanner. (C) Data analyzed with the Array Pro analyzer 493 
ver. 4.5. (D) Glyco-array analysis was performed using immune complex of soluble 494 
hDC-SIGN/Alexa555-anti-hDC-SIGN mAb as in sSIGNR1. 495 
 496 
Fig. 5. IL-10 production of RAW264.7 transfectants upon stimulation with glycan coated on 497 
plastic plate. 498 
(A) RAW-control, RAW-hDC-SIGN and RAW-chimera cells were analyzed by flowcytometry 499 
using polyclonal anti-hDC-SIGN Ab and anti-SIGNR1 mAb (22D1) specific to SIGNR1 CRD. 500 
(B) The transfectants (5 x 104 cells) were cultured on plates pre-coated with C. albicans J-1012 501 
and S. cerevisiae X2180-1A (WT) glycan in the presence or absence of LPS (100 ng/ml). After 502 
24 h, IL-10 in the supernatants was analyzed (upper panel). IL-10 production against S. 503 
cerevisiae glycan is shown as a percentage to that against C. albicans glycan (lower panel). (C) 504 
IL-10 production after stimulation with native and α-mannosidase-treated C. albicans J-1012 505 
glycan was analyzed as in B. IL-10 production against the treated glycan is shown as a 506 
percentage to that against the native glycan. **p = 0.0067, ***p = 0.0001 by Student’s t-test. 507 
TABLE 1. Composition of side chains and properties of N-glycan used in this study. 1 
                                                                                                                             2 
                                                                Presence of side chaina 3 
          N-glycan 5 
                                                                     α1,3-mannose   α1,2-mannose   α1,6-mannoseb   β1,2-mannose      PM 6 
 7 
C. albicans J-1012 (serotype A) + + + + + 8 
C. albicans NIH B-792 (serotype B) + + + + +	 9 
S. cerevisiae (WT) - +	 -	 -	 +	 10 
S. cerevisiae 4484-24D-1 (mnn1/mnn4) - +	 -	 -	 -	 11 
S. cerevisiae X2180-1A-5 (mnn2) -	 -	 -	 -	 -	 12 
C. stellatoidea +	 +	 +	 -	 -	 13 
C. parapsilosis +	 +	 -	 -	 -	 14 
C. lusitaniae -	 +	 -	 +	 +	 15 
C. albicans J-1012 (α-mannosidase treated) +	 +	 -	 +	 -	 16 
a PM, phosphorylated mannose. Side chain structure presence and absence in the N-glycan are indicated by + and -, respectively. 17 
b Branching in side chain. 18 
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(Galactosidase
treated)B PAA Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-PAA Glycotech 08-092
Lea PAA Galβ1-3(Fucα1-4)GlcNAcβ1-PAA Glycotech 01-035
[3S]Lea PAA (3OSO3)Galβ1-3(Fucα1-4)GlcNAcβ1-PAA Glycotech 01-040
Leb PAA Fucα1-2Galβ1-3(Fucα1-3)GlcNAcβ1-PAA Glycotech 08-042
Lex PAA Galβ1-4(Fucα1-3)GlcNAcβ1-PAA Glycotech 01-036
Ley PAA Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-PAA Glycotech 08-043
α cA5ueNAAPcA5ueN α 210-10hcetocylGAAP-2
α cG5ueNAAPcG5ueN α 150-10hcetocylGAAP-2
Sia2 PAA Neu5Acα2-8Neu5Acα2-PAA Glycotech 08-064
Sia3 PAA Neu5Acα2-8Neu5Acα2-8Neu5Acα2-PAA Glycotech 01-081
3'SiaLec PAA Neu5Ac 2 3Gal 3GlcNAc PAA Glycotech 01 078
-
OVM Glycoprotein Ovomucoid (Complex-type N-glycans) Sigma T2011
OVA Glycoprotein Ovoalbumin (Hybrid-type N-glycans) Sigma A2512
α naMAAPnaM α 500-10hcetocylGAAP-1
β naMAAPnaM β 050-10hcetocylGAAP-1
[6P]Man PAA ?6OPO4)Manα 600-10hcetocylGAAP-1
INV Glycoprotein Yeast invertase (High mannose-type N-glycans) Sigma I4504
cANlaGAAPnT α 010-10hcetocylGAAP-1
laGAAP1eroC β1-3GalNAcα1-PAA Glycotech 08-023
Core2 PAA Galβ1-3(GlcNAcβ1-6)GalNAcα1-PAA Glycotech 01-083
Core3 PAA GlcNAcβ1-3GalNAcα1-PAA Glycotech 01-071
α - β1-β1- -
3'SL PAA Neu5Acα2-3Galβ1-4Glcβ1-PAA Glycotech 01-038
3'SLN PAA Neu5Acα2-3Galβ1-4GlcNAcβ1-PAA Glycotech 01-077
sLea PAA Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-PAA Glycotech 08-044
sLex PAA Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-PAA Glycotech 01-045
6'SL PAA Neu5Acα2-6Galβ1-4Glcβ1-PAA Glycotech 01-039
FET Glycoprotein Fetuin (Complex-type N-glycans and O-glycans) Sigma F3004
AGP Glycoprotein α1-acid glycoprotein (Complex-type N-glycans ) Sigma G9885
TF Glycoprotein Transferrin (Complex-type N-glycans) Sigma T3309
TG Glycoprotein Porcine thyroglobulin (Complex and high-mannnose-type N-glycans) Sigma T1126
?
Core4 PAA GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1-PAA Glycotech 01-089
Forssman PAA GalNAcα1-3GalNAcβ1-PAA Glycotech 01-026
Core6 PAA GlcNAcβ1-6GalNAcα1-PAA Glycotech 01-072
laGAAP8eroC α1-3GalNAcα1-PAA Glycotech 01-028
?3’S]Core1 PAA ?3OSO3)Galβ1-3GalNAcα1-PAA Glycotech 08-069
Galβ-Core3 PAA Galβ1-4GlcNAcβ1-3GalNAcα1-PAA Glycotech 01-116
Asialo-BSM Glycoprotein Asialo bovine submaxillary mucin (Tn) Sigma M3895 (Acid-treated)
Asialo-GP Glycoprotein Asialo human glycophorin MN (T) Sigma A9791 (Acid-treated)
STn PAA Neu5Ac 2-6GalNAc 1-PAA Glycotech 01-059
β laGAAPlaG β 400-10hcetocylGAAP-1
[3S]βGal PAA ?3OSO3)Galβ 510-10hcetocylGAAP-1
cANlaGAAPid-A ?1-3Galβ1-PAA Glycotech 01-017
laGAAPcaL β1-4Glcβ 120-10hcetocylGAAP-1
Lec laGAAP β1-3GlcNAcβ1-PAA Glycotech 01-020
[3'S]Lec PAA (3OSO3)Galβ1-3GlcNAcβ1-PAA Glycotech 01-062
laGAAPNL β1-4GlcNAcβ1-PAA Glycotech 01-022
[3'S]LN PAA (3OSO3?Galβ1-4GlcNAcβ1-PAA Glycotech 01-061
[6S]LN PAA Galβ1-4(6OSO3)GlcNAcβ1-PAA Glycotech 01-066
[6'S]LN PAA (6OSO3)Galβ1-4GlcNAcβ1-PAA Glycotech 01-068
?G lNA PAA G lNA PAA Gl t h 01 011
STn (Gc) PAA Neu5Gcα2-6GalNAcα
α α
1-PAA Glycotech 01-107
ST PAA Neu5Acα2-3Galβ1-3GalNAcα1-PAA Glycotech 01-088
Siaα2-6Core 1 PAA Galβ1-3(Neu5Acα2-6)GalNAcα1-PAA Glycotech 01-113
BSM Glycoprotein Bovine submaxillary mucin (Sialyl Tn) Sigma M3895
GP Glycoprotein Human glycophorin (Disialyl T and sialyl Tn) Sigma G5017
α laGAAPlaG α 300-10hcetocylGAAP-1
Galα laGAAPlaG2-1 α1-2Galβ1-PAA Glycotech 01-056
Galα laGAAPlaG3-1 α1-3Galβ 810-10hcetocylGAAP-1
Galα1-3Lac PAA Galα1-3Galβ1-4Glcβ1-PAA Glycotech 01-075
Galα1-3LN PAA Galα1-3Galβ1-4GlcNAcβ1-PAA Glycotech 01-079
β a c a cβ1- yco ec -
di-GalNAcβ PAA GalNAcβ1-3GalNAcβ1-PAA Glycotech 01-070
LDN PAA GalNAcβ1-4GlcNAcβ1-PAA Glycotech 01-057
GA2 PAA GalNAcβ1-4Galβ1-4Glcβ1-PAA Glycotech 08-074
Asialo-FET Glycoprotein Asialo fetuin (Desialylated complex-type N- and O-glycans) Sigma F3004 (Acid-treated)
Asialo-AGP Glycoprotein Asialo α1-acid glycoprotein (Desialylated complex-type N-glycans) Sigma
G9885 (Acid-
treated)
Asialo-TF Glycoprotein Asialo transferrin (Desialylated complex-type N-glycans) Sigma T3309 (Acid-treated)
Asialo TG Glycoprotein Asialo porcine thyroglobulin (Desialylated complex-type N- Sigma T1126 (Acid-
Galα1-4LN PAA Galα1-4Galβ1-4GlcNAcβ1-PAA Glycotech 01-110
laGAAPesoibileM α1-6Glcβ 360-10hcetocylGAAP-1
α clGAAPclG α 100-10hcetocylGAAP-1
β clGAAPclG β 200-10hcetocylGAAP-1
clGAAPesotlaM α1-4Glcβ 450-10hcetocylGAAP-1
027004ukagakieSASB-dica cinorulayHASBAH
556004ukagakieSASB-A etafluS nitiorodnohCASBASC
066004ukagakieSASB-B etafluS nitiorodnohCASBBSC
007004ukagakieSASB-etafluS narapeHASBSH
590573mehcoiblaCASB-nirapeHASBPH
KS BSA Keratan Sulfate-BSA Seikagaku 400760- glycans, high-mannose-type N-glycans) treated)
 
α esonmahRAAPahR α 800-10hcetocylGAAP-1
Mannan (SC) Glycoprotein S. cerevisiae 4057MamgiSnannam
Mannan (CA) Glycoprotein C.albicans 100GMarakaTnannam
0524ZamgiSnasomyZnietorpocylGnasomyZ
Chitobiose PAA GlcNAcβ1-4GlcNAcβ1-PAA Glycotech 08-057
8367AamgiS-nietorpocylGASB
000-10hcetocylG-AAPAAP evitageN
Takahara et al.  Fig. S2.
Inhibition analysis by lectin ELISA. Binding of sSIGNR3 to C. albicans J-1012 glycan coated on microtiter 
plates was analyzed as in Fig. 2A. 
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